Topic: Lambert Eaton

The New York Times and PBS NewsHour report on a pharmaceutical "scam" where companies seek FDA approval for old, public-domain drugs to gain market monopolies. Specifically, a drug for Lambert-Eaton myasthenic syndrome, previously provided for free by Jacobus Pharmaceuticals, is being targeted for a massive price hike. The hosts argue that insurance companies and a lack of government price controls facilitate this exploitation.